• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

TheSUBWAY.Com Posts Stock Pick List: Stem Cell Innovations PluriCells(TM) Provide Alternative to the Presidential Veto!

Posted on: Tuesday, 25 July 2006, 21:01 CDT

TheSUBWAY.com names the following stocks to its Stock Pick List: Stem Cell Innovations, Inc. (OTCBB: SCLL), Symantec Corp. (NASDAQ: SYMC), Sirius Satellite Radio Inc. (Nasdaq:SIRI), Altus Pharmaceuticals Inc. (NASDAQ: ALTU).

Stem Cell Innovations, Inc. (OTCBB: SCLL) PluriCells(TM) provide an alternative to ES cells and are available for broad-based government funding. PluriCells are a type of pluripotent stem cell isolated from fetal tissue that have the ability to become all cell types of the body. Because they are developed from fetal germ cells, not viable embryos, they are eligible to be used in any NIH-funded laboratory. Stem cells derived from fetal germ cells were explicitly excluded from the Presidential ban by the Department of Health and Human Services guidance document of March 19, 2002

Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells(TM), have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Other stocks highlighted include Symantec Corp. (NASDAQ: SYMC): Stock Pick List, down 1% on 2 million shares, Sirius Satellite Radio Inc. (NASDAQ: SIRI): Stock Pick List, up 1% on 2 million shares, Altus Pharmaceuticals Inc. (NASDAQ: ALTU): Stock Pick List, down 1% on 3 million shares.

"Stocks have been hard-pressed to pick a direction in trading lately, going on a tear for a few days, only to see those gains wane in the next several sessions. The Dow Jones Industrial Average is, in fact, just now beginning to break out in the new year, still hovering slightly above the level it was at when the Federal Reserve began raising rates over a year ago." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated fifty thousand dollars for SCLL. CRG intends to sell its shares. CRG has sold approximately zero SCLL shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

 CONTACT: Capital Research Group Charles Tamburello 954-217-8555 www.TheSUBWAY.com

SOURCE: TheSUBWAY.com

Source: MARKET WIRE

More News in this Category